Evidence map›Paper›PMID 31257577›Full record

ArticleThe Journal of pathology2019

Autophagy contributes to BMP type 2 receptor degradation and development of pulmonary arterial hypertension.

Maria Catalina Gomez-Puerto, Iris van Zuijen, Christopher Jz Huang, Robert Szulcek, Xiaoke Pan, Maarten Ah van Dinther, Kondababu Kurakula, Catharina C Wiesmeijer, Marie-Jose Goumans, Harm-Jan Bogaard and 3 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 48 citations in OpenAlex.

  1. Review
  2. Fisetin alleviates pulmonary arterial hypertension by inhibiting the TGF-β1/Smad 2/3 signaling pathway.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Interplay between ALK2Cell death discovery · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Investigation of the Mechanism ofInternational journal of general medicine · 2024
    Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Maria Catalina Gomez-PuertoDepartment of Cell and Chemical Biology and Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0002-5362-9780
Iris van ZuijenDepartment of Cell and Chemical Biology and Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands.
Christopher Jz HuangDepartment of Medicine, University of Cambridge, Cambridge, UK.
Robert SzulcekDepartment of Cell and Chemical Biology and Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands.
Xiaoke PanAmsterdam UMC, Vrije Universiteit Amsterdam, Department of Pulmonary Medicine, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands.
Maarten Ah van DintherDepartment of Cell and Chemical Biology and Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0002-9451-8884
Kondababu KurakulaDepartment of Cell and Chemical Biology and Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands.
Catharina C WiesmeijerDepartment of Cell and Chemical Biology and Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands.
Marie-Jose GoumansDepartment of Cell and Chemical Biology and Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0001-9344-6746
Harm-Jan BogaardAmsterdam UMC, Vrije Universiteit Amsterdam, Department of Pulmonary Medicine, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands.
Nicholas W MorrellDepartment of Medicine, University of Cambridge, Cambridge, UK.
Amer Ahmed RanaDepartment of Medicine, University of Cambridge, Cambridge, UK.
Peter Ten DijkeDepartment of Cell and Chemical Biology and Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0002-7234-342X
Leiden University Medical Center · NLUniversity of Cambridge · GBAmsterdam Neuroscience · NL

Funding

British Heart Foundation PG/14/31/30786
6 · The paper itself

Abstract

Pulmonary arterial hypertension (PAH) is characterised by an increase in mean pulmonary arterial pressure which almost invariably leads to right heart failure and premature death. More than 70% of familial PAH and 20% of idiopathic PAH patients carry heterozygous mutations in the bone morphogenetic protein (BMP) type 2 receptor (BMPR2). However, the incomplete penetrance of BMPR2 mutations suggests that other genetic and environmental factors contribute to the disease. In the current study, we investigate the contribution of autophagy in the degradation of BMPR2 in pulmonary vascular cells. We demonstrate that endogenous BMPR2 is degraded through the lysosome in primary human pulmonary artery endothelial (PAECs) and smooth muscle cells (PASMCs): two cell types that play a key role in the pathology of the disease. By means of an elegant HaloTag system, we show that a block in lysosomal degradation leads to increased levels of BMPR2 at the plasma membrane. In addition, pharmacological or genetic manipulations of autophagy allow us to conclude that autophagy activation contributes to BMPR2 degradation. It has to be further investigated whether the role of autophagy in the degradation of BMPR2 is direct or through the modulation of the endocytic pathway. Interestingly, using an iPSC-derived endothelial cell model, our findings indicate that BMPR2 heterozygosity alone is sufficient to cause an increased autophagic flux. Besides BMPR2 heterozygosity, pro-inflammatory cytokines also contribute to an augmented autophagy in lung vascular cells. Furthermore, we demonstrate an increase in microtubule-associated protein 1 light chain 3 beta (MAP1LC3B) levels in lung sections from PAH induced in rats. Accordingly, pulmonary microvascular endothelial cells (MVECs) from end-stage idiopathic PAH patients present an elevated autophagic flux. Our findings support a model in which an increased autophagic flux in PAH patients contributes to a greater decrease in BMPR2 levels. Altogether, this study sheds light on the basic mechanisms of BMPR2 degradation and highlights a crucial role for autophagy in PAH. © 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.

Indexed as

AutophagyAdultAgedAged, 80 and overAnimalsArterial PressureBone Morphogenetic Protein Receptors, Type IICell LineCytokinesDisease Models, AnimalEndothelial CellsFemaleHeterozygoteHumansInflammation MediatorsLysosomesBMPR2 protein, humanBmpr2 protein, ratBone Morphogenetic Protein Receptors, Type IICytokinesInflammation MediatorsMicrotubule-Associated ProteinsautophagyBMPR2BMPR2+/− iPSC-ECshuman pulmonary artery endothelial cells (PAECs)human pulmonary artery smooth muscle cells (PASMCs)inflammationpulmonary arterial hypertension (PAH)

Identifiers

PMID31257577
PMCPMC6852495
OpenAlexW2955467892

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.